TN2011000272A1 - Dosage regimen for a s1p agonist - Google Patents

Dosage regimen for a s1p agonist

Info

Publication number: TN2011000272A1
Authority: TN; Tunisia
Prior art keywords: dosage regimen; agonist; dosage; daily dosage; agonists
Prior art date: 2008-12-22

Application number

TN2011000272A

Other languages

English (en)

Inventor

Robert Schmouder

Thomas Dumortier

Olivier David

Michael Looby

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-22

Filing date

2011-05-26

Publication date

2012-12-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41667217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000272(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-05-26 Application filed by Novartis Ag filed Critical Novartis Ag

2012-12-17 Publication of TN2011000272A1 publication Critical patent/TN2011000272A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TN2011000272A 2008-12-22 2011-05-26 Dosage regimen for a s1p agonist TN2011000272A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US13967208P	2008-12-22	2008-12-22
US21853009P	2009-06-19	2009-06-19
US24671509P	2009-09-29	2009-09-29
PCT/US2009/068888 WO2010075239A1 (fr)	2008-12-22	2009-12-21	Régime posologique pour un agoniste du récepteur s1p

Publications (1)

Publication Number	Publication Date
TN2011000272A1 true TN2011000272A1 (en)	2012-12-17

Family

ID=41667217

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000272A TN2011000272A1 (en)	2008-12-22	2011-05-26	Dosage regimen for a s1p agonist

Country Status (43)

Country	Link
US (12)	US20110257133A1 (fr)
EP (7)	EP3453387B1 (fr)
JP (7)	JP2012513401A (fr)
KR (1)	KR101347919B1 (fr)
CN (1)	CN102264359A (fr)
AR (1)	AR074826A1 (fr)
AU (1)	AU2009330176C9 (fr)
BR (1)	BRPI0923500A2 (fr)
CA (1)	CA2747802C (fr)
CL (2)	CL2011001529A1 (fr)
CO (1)	CO6390117A2 (fr)
CR (1)	CR20110274A (fr)
CU (1)	CU20110136A7 (fr)
CY (4)	CY1116990T1 (fr)
DK (4)	DK2379067T3 (fr)
EA (1)	EA201100978A1 (fr)
EC (1)	ECSP11011222A (fr)
ES (4)	ES2760607T3 (fr)
FI (2)	FI4098256T3 (fr)
FR (2)	FR20C1060I1 (fr)
HN (1)	HN2011001759A (fr)
HR (4)	HRP20250568T1 (fr)
HU (6)	HUE052048T2 (fr)
IL (3)	IL213170A0 (fr)
LT (5)	LT3453387T (fr)
LU (1)	LUC00183I2 (fr)
MA (1)	MA32981B1 (fr)
ME (2)	ME03594B (fr)
MX (3)	MX385959B (fr)
NO (1)	NO2020038I1 (fr)
NZ (1)	NZ593065A (fr)
PE (1)	PE20120337A1 (fr)
PL (4)	PL2379067T3 (fr)
PT (4)	PT2379067E (fr)
RS (3)	RS60666B1 (fr)
SG (1)	SG171404A1 (fr)
SI (4)	SI3409274T1 (fr)
SM (2)	SMT202000054T1 (fr)
TN (1)	TN2011000272A1 (fr)
TW (1)	TW201028143A (fr)
UY (1)	UY32352A (fr)
WO (1)	WO2010075239A1 (fr)
ZA (2)	ZA201103863B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20170246T4 (hr)	2008-03-17	2020-02-07	Actelion Pharmaceuticals Ltd.	Režim doziranja za selektivni agonist s1p1-receptora
LT3453387T (lt)	2008-12-22	2020-08-25	Novartis Ag	S1p receptoriaus antagonisto dozavimo režimas
SG178987A1 (en)	2009-09-29	2012-04-27	Novartis Ag	Dosage regimen of an s1p receptor modulator
US20110124605A1 (en) *	2009-11-20	2011-05-26	Shreeram Aradhye	Use of an S1P Receptor Agonist
EP4148045A1 (fr)	2010-01-27	2023-03-15	Arena Pharmaceuticals, Inc.	Composés intermédiaires pour la préparation de l'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclopenta[b]indol-3-yl) acétique et de ses sels
CN102917698A (zh) *	2010-05-06	2013-02-06	诺瓦提斯公司	二芳基硫醚衍生物的给药方案
EP2455080A1 (fr) *	2010-11-23	2012-05-23	Almirall, S.A.	Agonistes de récepteur S1P1 à utiliser dans le traitement de la sclérose en plaques
FR2968556B1 (fr)	2010-12-13	2013-12-27	Centre Nat Rech Scient	Inhibiteurs des infections a vih et leurs utilisations
HRP20191842T1 (hr)	2011-01-07	2019-12-27	Novartis Ag	Formulacije imunosupresiva
EP3502236B1 (fr)	2011-02-18	2023-08-23	The Scripps Research Institute	Différenciation dirigée de cellules précurseurs d'oligodendrocytes vers un destin de cellules myélinisantes
AR085749A1 (es)	2011-04-01	2013-10-23	Novartis Ag	Formulaciones
WO2012162392A1 (fr) *	2011-05-23	2012-11-29	Timothy Hla	Matériaux protecteurs de l'endothélium et procédés d'utilisation
TW201320994A (zh)	2011-10-11	2013-06-01	Novartis Ag	投藥療程
EP2885266B1 (fr)	2012-08-17	2020-03-18	Actelion Pharmaceuticals Ltd	Procédé pour la préparation du (2z,5z)-5-(3-chloro-4-((r)-2,3-dihydroxypropoxy)benzylidène)-2-(propylimino)-3-(o-tolyl)thiazolidin-4-one et intermédiaire utilisé dans ce procédé
EP2964249A1 (fr) *	2013-03-06	2016-01-13	Acorda Therapeutics, Inc.	Dosage thérapeutique d'une neuréguline ou d'un fragment associé pour le traitement ou la prophylaxie de l'insuffisance cardiaque
EP3054933A4 (fr)	2013-10-11	2017-03-15	Teikoku Pharma USA, Inc.	Formulations topiques agonistes du récepteur de la sphingosine-1-phosphate et procédés d'utilisation de celles-ci
US10675254B2 (en)	2013-10-11	2020-06-09	Teikoku Seiyaku Co., Ltd.	Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same
TW201622721A (zh) *	2014-04-10	2016-07-01	諾華公司	Ｓ１ｐ調節劑之立即釋放劑量療法
KR102590068B1 (ko)	2014-12-11	2023-10-16	액테리온 파마슈티칼 리미티드	선택적 s1p1 수용체 효능제에 대한 투약 섭생
MA41139A (fr)	2014-12-11	2017-10-17	Actelion Pharmaceuticals Ltd	Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
AU2016205361C1 (en) *	2015-01-06	2021-04-08	Arena Pharmaceuticals, Inc.	Methods of treating conditions related to the S1P1 receptor
CA2973540A1 (fr)	2015-02-26	2016-09-01	Novartis Ag	Traitement de maladie auto-immune chez un patient recevant en outre un betabloquant
CA3002551A1 (fr)	2015-06-22	2016-12-29	Arena Pharmaceuticals, Inc.	Sel cristallin de l-arginine de (r)(7-(4-cyclopentyle-3-(trifluoromethyle)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acide acetique(compose 1) aux fins d'utilisation contre les troubles associes au recepteur s1p1
WO2018151834A1 (fr)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
CA3053418A1 (fr)	2017-02-16	2018-08-23	Arena Pharmaceuticals, Inc.	Composes et methodes de traitement de l'angiocholite biliaire primitive
CA3102136A1 (fr)	2018-06-06	2019-12-12	Arena Pharmaceuticals, Inc.	Methodes de traitement de troubles associes au recepteur s1p1<sb />
MX2022005014A (es)	2019-10-31	2022-05-16	Idorsia Pharmaceuticals Ltd	Combinacion de un antagonista de cxcr7 con un modulador del receptor s1p1.
WO2021158848A1 (fr) *	2020-02-07	2021-08-12	Argentum Pharmaceuticals Llc	Régime posologique d'un agoniste du récepteur s1p
US11135197B2 (en)	2020-02-07	2021-10-05	Argentum Pharmaceuticals Llc	Dosage regimen of an S1P receptor modulator
JP2023515612A (ja) *	2020-02-28	2023-04-13	アカール・ファーマ・プロプライエタリー・リミテッド	Ｓ１ｐ受容体調節物質
CN113332435B (zh) *	2021-06-18	2022-10-18	广州中医药大学(广州中医药研究院)	鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2579602B2 (ja)	1992-10-21	1997-02-05	吉富製薬株式会社	２−アミノ−１，３−プロパンジオール化合物および免疫抑制剤
AU2001285331B2 (en)	2000-08-31	2006-04-06	Merck & Co., Inc.	Phosphate derivatives as immunoregulatory agents
PT1505959E (pt)	2002-05-16	2009-02-05	Novartis Ag	Utilização de agentes de ligação do receptor edg em cancro
JP4861177B2 (ja) *	2003-09-12	2012-01-25	ニューロノバエービー	神経系の障害の処置
US20060002999A1 (en) *	2004-06-17	2006-01-05	Forest Laboratories, Inc.	Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
CN102600472A (zh) *	2004-11-29	2012-07-25	诺瓦提斯公司	S1p受体激动剂的剂量方案
EP1688141A1 (fr) *	2005-01-31	2006-08-09	elbion AG	Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
CN101541227B (zh) *	2005-02-10	2013-06-05	G.I.视频有限公司	用于带导向元件的胃肠工具的前进技术
CA2925175A1 (fr) *	2007-10-12	2009-04-16	Novartis Ag	Compositions comprenant des modulateurs du recepteur de sphingosine 1-phosphate (s1p)
HRP20170246T4 (hr) *	2008-03-17	2020-02-07	Actelion Pharmaceuticals Ltd.	Režim doziranja za selektivni agonist s1p1-receptora
KR20170081755A (ko) *	2008-06-20	2017-07-12	노파르티스 아게	다발성 경화증을 치료하기 위한 소아용 조성물
DK2379069T3 (en)	2008-12-22	2015-06-08	Novartis Ag	Dosage Plan for an S1P receptor agonist
LT3453387T (lt)	2008-12-22	2020-08-25	Novartis Ag	S1p receptoriaus antagonisto dozavimo režimas

2009
- 2009-12-21 LT LTEP18201062.9T patent/LT3453387T/lt unknown
- 2009-12-21 PE PE2011001265A patent/PE20120337A1/es not_active Application Discontinuation
- 2009-12-21 AR ARP090105010A patent/AR074826A1/es not_active Application Discontinuation
- 2009-12-21 FI FIEP22187007.4T patent/FI4098256T3/fi active
- 2009-12-21 US US13/141,552 patent/US20110257133A1/en not_active Abandoned
- 2009-12-21 KR KR1020117017073A patent/KR101347919B1/ko active Active
- 2009-12-21 SI SI200932015T patent/SI3409274T1/sl unknown
- 2009-12-21 DK DK09797234.3T patent/DK2379067T3/en active
- 2009-12-21 LT LTEP22187007.4T patent/LT4098256T/lt unknown
- 2009-12-21 US US12/642,892 patent/US20100160259A1/en not_active Abandoned
- 2009-12-21 PT PT97972343T patent/PT2379067E/pt unknown
- 2009-12-21 EP EP18201062.9A patent/EP3453387B1/fr active Active
- 2009-12-21 PT PT182010629T patent/PT3453387T/pt unknown
- 2009-12-21 ME MEP-2019-339A patent/ME03594B/fr unknown
- 2009-12-21 EP EP15158251.7A patent/EP2907511A1/fr not_active Withdrawn
- 2009-12-21 ES ES18179301T patent/ES2760607T3/es active Active
- 2009-12-21 HU HUE18201062A patent/HUE052048T2/hu unknown
- 2009-12-21 ES ES22187007T patent/ES3017254T3/es active Active
- 2009-12-21 SG SG2011037629A patent/SG171404A1/en unknown
- 2009-12-21 PT PT221870074T patent/PT4098256T/pt unknown
- 2009-12-21 SI SI200931311T patent/SI2379067T1/sl unknown
- 2009-12-21 UY UY0001032352A patent/UY32352A/es not_active Application Discontinuation
- 2009-12-21 BR BRPI0923500-0A patent/BRPI0923500A2/pt not_active Application Discontinuation
- 2009-12-21 ES ES09797234.3T patent/ES2552823T3/es active Active
- 2009-12-21 ME MEP-2020-156A patent/ME03802B/fr unknown
- 2009-12-21 ES ES18201062T patent/ES2810823T3/es active Active
- 2009-12-21 NZ NZ593065A patent/NZ593065A/xx not_active IP Right Cessation
- 2009-12-21 EP EP16182876.9A patent/EP3120844A1/fr not_active Withdrawn
- 2009-12-21 EP EP20160225.7A patent/EP3677260A1/fr active Pending
- 2009-12-21 LT LTEP18179301.9T patent/LT3409274T/lt unknown
- 2009-12-21 JP JP2011542521A patent/JP2012513401A/ja not_active Withdrawn
- 2009-12-21 SI SI200932080T patent/SI3453387T1/sl unknown
- 2009-12-21 PL PL09797234T patent/PL2379067T3/pl unknown
- 2009-12-21 HR HRP20250568TT patent/HRP20250568T1/hr unknown
- 2009-12-21 EA EA201100978A patent/EA201100978A1/ru unknown
- 2009-12-21 DK DK18201062.9T patent/DK3453387T3/da active
- 2009-12-21 SM SM20200054T patent/SMT202000054T1/it unknown
- 2009-12-21 HU HUE22187007A patent/HUE071189T2/hu unknown
- 2009-12-21 EP EP09797234.3A patent/EP2379067B1/fr not_active Revoked
- 2009-12-21 PL PL18201062T patent/PL3453387T3/pl unknown
- 2009-12-21 SI SI200932211T patent/SI4098256T1/sl unknown
- 2009-12-21 TW TW098143960A patent/TW201028143A/zh unknown
- 2009-12-21 HR HRP20151190TT patent/HRP20151190T1/hr unknown
- 2009-12-21 RS RS20200900A patent/RS60666B1/sr unknown
- 2009-12-21 AU AU2009330176A patent/AU2009330176C9/en not_active Withdrawn - After Issue
- 2009-12-21 CN CN2009801518640A patent/CN102264359A/zh active Pending
- 2009-12-21 WO PCT/US2009/068888 patent/WO2010075239A1/fr not_active Ceased
- 2009-12-21 HU HUE09797234A patent/HUE026869T2/en unknown
- 2009-12-21 CA CA2747802A patent/CA2747802C/fr active Active
- 2009-12-21 PL PL22187007.4T patent/PL4098256T3/pl unknown
- 2009-12-21 DK DK18179301.9T patent/DK3409274T3/da active
- 2009-12-21 RS RS20250452A patent/RS66784B9/sr unknown
- 2009-12-21 EP EP22187007.4A patent/EP4098256B9/fr active Active
- 2009-12-21 MA MA34034A patent/MA32981B1/fr unknown
- 2009-12-21 PT PT181793019T patent/PT3409274T/pt unknown
- 2009-12-21 PL PL18179301T patent/PL3409274T3/pl unknown
- 2009-12-21 SM SM20200441T patent/SMT202000441T1/it unknown
- 2009-12-21 DK DK22187007.4T patent/DK4098256T5/da active
- 2009-12-21 MX MX2018006099A patent/MX385959B/es unknown
- 2009-12-21 HU HUE18179301A patent/HUE048717T4/hu unknown
- 2009-12-21 EP EP18179301.9A patent/EP3409274B1/fr not_active Revoked
- 2009-12-21 RS RS20191546A patent/RS59857B1/sr unknown
- 2009-12-21 MX MX2011006623A patent/MX2011006623A/es unknown
2011
- 2011-05-25 ZA ZA2011/03863A patent/ZA201103863B/en unknown
- 2011-05-25 CR CR20110274A patent/CR20110274A/es not_active Application Discontinuation
- 2011-05-26 TN TN2011000272A patent/TN2011000272A1/fr unknown
- 2011-05-26 IL IL213170A patent/IL213170A0/en unknown
- 2011-06-17 MX MX2021010759A patent/MX2021010759A/es unknown
- 2011-06-21 CL CL2011001529A patent/CL2011001529A1/es unknown
- 2011-06-22 CU CU20110136A patent/CU20110136A7/es unknown
- 2011-06-22 HN HN2011001759A patent/HN2011001759A/es unknown
- 2011-06-22 EC EC2011011222A patent/ECSP11011222A/es unknown
- 2011-06-23 CO CO11079290A patent/CO6390117A2/es not_active Application Discontinuation
2012
- 2012-08-06 ZA ZA2012/05942A patent/ZA201205942B/en unknown
2013
- 2013-05-31 CL CL2013001558A patent/CL2013001558A1/es unknown
- 2013-09-06 US US14/020,058 patent/US20140066657A1/en not_active Abandoned
2014
- 2014-01-31 US US14/169,660 patent/US20140148415A1/en not_active Abandoned
- 2014-04-10 JP JP2014080892A patent/JP2014144970A/ja not_active Withdrawn
2015
- 2015-10-14 JP JP2015202669A patent/JP2016135752A/ja not_active Withdrawn
- 2015-11-30 CY CY20151101084T patent/CY1116990T1/el unknown
- 2015-12-02 US US14/956,855 patent/US20160081949A1/en not_active Abandoned
2016
- 2016-05-23 US US15/161,778 patent/US20160263061A1/en not_active Abandoned
2017
- 2017-03-06 JP JP2017041331A patent/JP2017141238A/ja not_active Withdrawn
- 2017-03-21 US US15/465,091 patent/US20170189353A1/en not_active Abandoned
2018
- 2018-06-11 US US16/005,137 patent/US20180289638A1/en not_active Abandoned
- 2018-11-26 US US16/199,905 patent/US20190091180A1/en not_active Abandoned
2019
- 2019-05-22 JP JP2019095899A patent/JP7329965B2/ja active Active
- 2019-12-02 HR HRP20192175TT patent/HRP20192175T1/hr unknown
- 2019-12-03 CY CY20191101264T patent/CY1122812T1/el unknown
2020
- 2020-05-05 US US16/867,293 patent/US20200330407A1/en not_active Abandoned
- 2020-05-18 IL IL274756A patent/IL274756A/en unknown
- 2020-07-27 HR HRP20201167TT patent/HRP20201167T1/hr unknown
- 2020-08-03 CY CY20201100712T patent/CY1123255T1/el unknown
- 2020-11-17 LU LU00183C patent/LUC00183I2/fr unknown
- 2020-11-17 LT LTPA2020005C patent/LTPA2020005I1/lt unknown
- 2020-11-18 NO NO2020038C patent/NO2020038I1/no unknown
- 2020-11-19 FR FR20C1060C patent/FR20C1060I1/fr active Active
- 2020-11-19 CY CY2020036C patent/CY2020036I2/el unknown
- 2020-11-19 HU HUS2000046C patent/HUS2000046I1/hu unknown
- 2020-11-23 IL IL278914A patent/IL278914A/en unknown
2021
- 2021-09-20 US US17/479,649 patent/US20220142949A1/en not_active Abandoned
2022
- 2022-04-21 JP JP2022070231A patent/JP2022103194A/ja active Pending
2024
- 2024-06-06 JP JP2024092377A patent/JP2024129030A/ja active Pending
- 2024-09-27 US US18/900,154 patent/US20250262171A1/en active Pending
2025
- 2025-04-08 FR FR25C1012C patent/FR25C1012I1/fr active Active
- 2025-05-19 LT LTPA2025520C patent/LTPA2025520I1/lt unknown
- 2025-05-23 FI FIC20253002C patent/FIC20253002I1/fi unknown
- 2025-06-13 HU HUS2500026C patent/HUS2500026I1/hu unknown

Also Published As

Publication number	Publication date
HRP20201167T1 (hr)	2020-12-11
KR101347919B1 (ko)	2014-01-07
CY1116990T1 (el)	2017-04-05
PT2379067E (pt)	2015-12-23
HUS2500026I1 (hu)	2025-07-28
SI2379067T1 (sl)	2016-01-29
PT4098256T (pt)	2025-04-10
CA2747802C (fr)	2021-02-09
HUE071189T2 (hu)	2025-08-28
SMT202000054T1 (it)	2020-03-13
AU2009330176B2 (en)	2014-03-06
ME03594B (fr)	2020-07-20
US20160081949A1 (en)	2016-03-24
LTPA2020005I1 (lt)	2020-12-10
HUE048717T2 (hu)	2020-08-28
IL274756A (en)	2020-07-30
ZA201205942B (en)	2013-03-27
RS59857B1 (sr)	2020-02-28
CY1122812T1 (el)	2021-05-05
PT3453387T (pt)	2020-08-11
HUS2000046I1 (hu)	2020-12-28
DK3409274T3 (da)	2019-12-16
JP7329965B2 (ja)	2023-08-21
US20170189353A1 (en)	2017-07-06
US20200330407A1 (en)	2020-10-22
RS66784B1 (sr)	2025-06-30
CR20110274A (es)	2011-07-19
KR20110096175A (ko)	2011-08-29
UY32352A (es)	2010-07-30
LTPA2025520I1 (fr)	2025-06-25
FR20C1060I1 (fr)	2020-12-25
US20100160259A1 (en)	2010-06-24
NZ593065A (en)	2012-11-30
ES2552823T3 (es)	2015-12-02
EP4098256A1 (fr)	2022-12-07
SG171404A1 (en)	2011-07-28
JP2016135752A (ja)	2016-07-28
CA2747802A1 (fr)	2010-07-01
ES3017254T3 (en)	2025-05-12
CL2013001558A1 (es)	2013-10-25
JP2012513401A (ja)	2012-06-14
FIC20253002I1 (fi)	2025-05-23
PL3453387T3 (pl)	2020-11-02
AU2009330176C9 (en)	2017-01-05
PT3409274T (pt)	2019-12-17
JP2024129030A (ja)	2024-09-26
JP2014144970A (ja)	2014-08-14
PL2379067T3 (pl)	2016-02-29
EP2379067A1 (fr)	2011-10-26
CU20110136A7 (es)	2012-01-31
ES2810823T3 (es)	2021-03-09
ES2760607T3 (es)	2020-05-14
JP2022103194A (ja)	2022-07-07
ZA201103863B (en)	2012-10-31
FR25C1012I1 (fr)	2025-06-13
CO6390117A2 (es)	2012-02-29
JP2017141238A (ja)	2017-08-17
US20250262171A1 (en)	2025-08-21
EP3453387A1 (fr)	2019-03-13
NO2020038I1 (no)	2020-11-18
EP3120844A1 (fr)	2017-01-25
WO2010075239A1 (fr)	2010-07-01
LT3453387T (lt)	2020-08-25
EP2379067B1 (fr)	2015-09-02
ME03802B (fr)	2021-04-20
US20190091180A1 (en)	2019-03-28
PL4098256T3 (pl)	2025-06-09
EP2907511A1 (fr)	2015-08-19
CN102264359A (zh)	2011-11-30
PE20120337A1 (es)	2012-04-24
SI3409274T1 (sl)	2020-03-31
US20140066657A1 (en)	2014-03-06
TW201028143A (en)	2010-08-01
HRP20192175T1 (hr)	2020-03-20
FI4098256T3 (fi)	2025-03-31
EP3453387B1 (fr)	2020-06-03
HUE026869T2 (en)	2016-08-29
HN2011001759A (es)	2013-11-26
EP4098256B1 (fr)	2025-02-26
CL2011001529A1 (es)	2012-02-24
RS60666B1 (sr)	2020-09-30
HUE048717T4 (hu)	2022-02-28
EP4098256B9 (fr)	2025-06-18
JP2019167360A (ja)	2019-10-03
HUE052048T2 (hu)	2021-04-28
EP3677260A1 (fr)	2020-07-08
ECSP11011222A (es)	2011-08-31
CY2020036I2 (el)	2021-06-25
IL213170A0 (en)	2011-07-31
MX385959B (es)	2025-03-18
AU2009330176A1 (en)	2011-07-07
LT3409274T (lt)	2020-02-10
US20220142949A1 (en)	2022-05-12
AU2009330176C1 (en)	2016-12-08
PL3409274T3 (pl)	2020-06-01
HRP20250568T1 (hr)	2025-07-04
MX2011006623A (es)	2011-07-12
RS66784B9 (sr)	2025-08-29
EP3409274B1 (fr)	2019-11-20
US20110257133A1 (en)	2011-10-20
AR074826A1 (es)	2011-02-16
US20180289638A1 (en)	2018-10-11
MX2021010759A (es)	2022-07-19
DK2379067T3 (en)	2015-12-07
SMT202000441T1 (it)	2020-09-10
EA201100978A1 (ru)	2012-01-30
LUC00183I2 (fr)	2024-07-01
SI3453387T1 (sl)	2020-10-30
US20140148415A1 (en)	2014-05-29
DK3453387T3 (da)	2020-08-10
DK4098256T3 (da)	2025-04-22
CY1123255T1 (el)	2021-10-29
CY2020036I1 (el)	2021-03-12
BRPI0923500A2 (pt)	2018-05-29
IL278914A (en)	2021-01-31
EP3409274A1 (fr)	2018-12-05
HRP20151190T1 (hr)	2016-01-01
DK4098256T5 (da)	2025-07-21
LT4098256T (lt)	2025-06-10
SI4098256T1 (sl)	2025-06-30
US20160263061A1 (en)	2016-09-15
MA32981B1 (fr)	2012-01-02

Publication	Publication Date	Title
TN2011000272A1 (en)	2012-12-17	Dosage regimen for a s1p agonist
TN2011000281A1 (en)	2012-12-17	Dosage regimen of an s1p receptor agonist
PH12017501495A1 (en)	2018-07-02	Dosage regimen of an s1p receptor modulator
MX2009006304A (es)	2009-06-23	Nuevos compuestos de oxadiazol.
MX2012000704A (es)	2012-03-07	Agonistas de gpr119.
EA201491607A1 (ru)	2015-07-30	Модуляторы толлподобных рецепторов
CL2008002129A1 (es)	2008-11-21	Compuestos derivados de (1h-indazol-3-il)-amidas sustituidas, inhibidores de quinasa; composicion farmaceutica; procedimiento de preparacion; y uso del compuesto para el tratamiento del cancer.
MX2012012771A (es)	2012-12-17	Terapia de combinacion.
MX2012011631A (es)	2013-01-18	Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo.
EA201170198A1 (ru)	2011-08-30	Фармацевтические композиции, содержащие лиганды рецептора дофамина
MX2011013437A (es)	2012-02-21	Antagonista y agonistas inversos de histamina h3 y metodos para el uso de los mismos.
GB0812642D0 (en)	2008-08-20	Compounds
CL2009002017A1 (es)	2011-01-07	Uso de un agonista de esfingosina-1-fosfato (s1p) derivado de aminopropanodiol para tratar la malaria cerebral; formulacion farmaceutica y forma farmaceutica que comprende el agonista de s1p y un farmaco antimalaria.
MX2007010752A (es)	2007-09-12	Usos oftalmicos de moduladores de receptor s1p.
MX2009008191A (es)	2009-08-12	Medicamento para el tratamiento de endometriosis.
MX2011008458A (es)	2011-09-01	Metodos para preparar agonistas y antagonistas del receptor s1p.
JO2979B1 (en)	2016-03-15	Cyclopropyl compounds
CU20130155A7 (es)	2014-02-28	Régimen de dosificación para un agonista de los receptores de s1p
UA106219C2 (ru)	2014-08-11	Модуляторы толл-подобных рецепторов
CL2010000497A1 (es)	2011-03-11	Uso de compuestos derivados de indol para el tratamiento del dolor visceral; compuestos específicos derivados de indol; procedimiento de preparación de un compuesto; composición farmacéutica y uso para el tratamiento de una condición causada por la acción de nos.
UA105483C2 (uk)	2014-05-26	Похідні ізохінолінону, композиція на їх основі та застосування як інгібіторів рі3k